GlobeNewsWire
15 Jun 2026, 10:33 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Culper Research alleges ADMA Biologics engaged in a channel stuffing scheme to report 20% growth in 2025 when real growth was actually -3%. — Allegations of systemic revenue fraud and artificial growth are fundamental red flags that severely damage investor trust and valuation.
-0.90A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives following a nearly 30% stock price drop. — Legal proceedings for securities fraud create long-term financial liability and regulatory risk for the company.
-0.60Cantor downgraded ADMA Biologics' stock rating due to concerns raised by the short seller report. — A downgrade from a major financial institution validates the bearish thesis and typically triggers further institutional selling.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and a significant stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
